Efficacy and safety of canagliflozin as add‐on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24‐week, randomized, double‐blind, placebo‐controlled trial

AIMS: To investigate efficacy and safety of the sodium–glucose co‐transporter 2 (SGLT2) inhibitor canagliflozin administered as add‐on therapy to the dipeptidyl peptidase‐4 (DPP‐4) inhibitor teneligliptin in patients with type 2 diabetes mellitus (T2DM). MATERIALS AND METHODS: We conducted a multice...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Diabetes Obes Metab
Päätekijät: Kadowaki, Takashi, Inagaki, Nobuya, Kondo, Kazuoki, Nishimura, Kenichi, Kaneko, Genki, Maruyama, Nobuko, Nakanishi, Nobuhiro, Iijima, Hiroaki, Watanabe, Yumi, Gouda, Maki
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Blackwell Publishing Ltd 2017
Aiheet:
Original Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5484989/
https://ncbi.nlm.nih.gov/pubmed/28177187
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.12898
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia